Patrakka J, Kestilä M, Wartiovaara J, Ruotsalainen V, Tissari P, Lenkkeri U, Männikkö M, Visapää I, Holmberg C, Rapola J, Tryggvason K, Jalanko H
Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
Kidney Int. 2000 Sep;58(3):972-80. doi: 10.1046/j.1523-1755.2000.00254.x.
Congenital nephrotic syndrome (NPHS1) is a rare disease inherited as an autosomally recessive trait. The NPHS1 gene mutated in NPHS1 children has recently been identified. The gene codes for nephrin, a cell-surface protein of podocytes. Two mutations, named Fin-major and Fin-minor, have been found in over 90% of the Finnish patients. In this study, we correlated the NPHS1 gene mutations to the clinical features and renal findings in 46 Finnish NPHS1 children.
Clinical data were collected from patient files, and kidney histology and electron microscopy samples were re-evaluated. The expression of nephrin was studied using immunohistochemistry, Western blotting, and in situ hybridization.
Nephrotic syndrome was detected in most patients within days after birth regardless of the genotype detected. No difference could be found in neonatal, renal, cardiac, or neurological features in patients with different mutations. Nephrin was not expressed in kidneys with Fin-major or Fin-minor mutations, while another slit diaphragm-associated protein, ZO-1, stained normally. In electron microscopy, podocyte fusion and podocyte filtration slits of various sizes were detected. The slit diaphragms, however, were missing. In contrast to this, a nephrotic infant with Fin-major/R743C genotype expressed nephrin in kidney had normal slit diaphragms and responded to therapy with an angiotensin-converting enzyme inhibitor and indomethacin.
The most common NPHS1 gene mutations, Fin-major and Fin-minor, both lead to an absence of nephrin and podocyte slit diaphragms, as well as a clinically severe form of NPHS1, the Finnish type of congenital nephrotic syndrome.
先天性肾病综合征(NPHS1)是一种罕见的常染色体隐性遗传疾病。最近已鉴定出在NPHS1患儿中发生突变的NPHS1基因。该基因编码足细胞的一种细胞表面蛋白——nephrin。在超过90%的芬兰患者中发现了两种名为Fin-major和Fin-minor的突变。在本研究中,我们将46例芬兰NPHS1患儿的NPHS1基因突变与临床特征及肾脏检查结果进行了关联分析。
从患者病历中收集临床数据,并对肾脏组织学和电子显微镜样本进行重新评估。使用免疫组织化学、蛋白质印迹法和原位杂交技术研究nephrin的表达。
无论检测到何种基因型,大多数患者在出生后数天内即被诊断为肾病综合征。不同突变患者在新生儿、肾脏、心脏或神经学特征方面未发现差异。在具有Fin-major或Fin-minor突变的肾脏中未检测到nephrin表达,而另一种与裂孔隔膜相关的蛋白——ZO-1,染色正常。在电子显微镜下,检测到足细胞融合及各种大小的足细胞滤过裂隙。然而,裂孔隔膜缺失。与此形成对比的是,一名具有Fin-major/R743C基因型的肾病婴儿在肾脏中表达nephrin,具有正常的裂孔隔膜,并且对血管紧张素转换酶抑制剂和吲哚美辛治疗有反应。
最常见的NPHS1基因突变,即Fin-major和Fin-minor,均导致nephrin和足细胞裂孔隔膜缺失,以及临床上严重形式的NPHS1,即芬兰型先天性肾病综合征。